Literature DB >> 7398733

Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.

W J Leahey, J D Neill, M P Varma, R G Shanks.   

Abstract

Observations were made in 5 healthy subjects who exercised before and 1, 3, 6, 8 and 24 h after the oral administration on separate occasions of 160 mg oxprenolol, 160 mg slow release oxprenolol, 160 mg long acting propranolol and 400 mg sotalol. Blood samples were obtained before and at 1, 2, 3, 6, 8, 10 and 24 h after drug administration and assayed for drug concentration. Although the plasma concentration of oxprenolol after S.R. oxprenolol was significantly less at 1 and 2 h and significantly greater at 24 h than after conventional oxprenolol, there was little difference between the effects of the two drugs on an exercise tachycardia. The plasma level of propranolol and the reduction in an exercise tachycardia after L.A. propranolol increased slowly to reach a peak at 6 h and then declined gradually to 24 h. The maximum plasma concentration and effect after sotalol occurred at 3 h and then declined with an elimination half-life of 12.1 h. At 24 h the percentage reduction in an exercise tachycardia was 8.3 +/- 2.5 after oxprenolol, 10.0 +/- 2.3 after S.R. oxprenolol, 18.0 +/- 3.2 after L.A. propranolol and 14.7 +/- 3.4% after sotalol.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7398733     DOI: 10.1007/bf00570158

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography.

Authors:  P H Degen; W Riess
Journal:  J Chromatogr       Date:  1976-06-09

2.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

3.  Observations on the efficacy and pharmacokinetics of sotalol after oral administration.

Authors:  H C Brown; S G Carruthers; J G Kelly; D G McDevitt; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

4.  Evaluation of once daily sotalol administration in man.

Authors:  D G McDewitt; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

5.  Separation and spectrofluorometric assay of the -adrenergic blocker sotalol from blood and urine.

Authors:  E R Garrett; K Schnelle
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

6.  To be taken as directed.

Authors:  M S Gatley
Journal:  J R Coll Gen Pract       Date:  1968-07

7.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

8.  Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

Authors:  J McAinsh; N S Baber; R Smith; J Young
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

9.  Bioavailability of conventional and slow-release oxprenolol in fasted and nonfasted individuals.

Authors:  C P Dawes; M J Kendall; P G Welling
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

10.  Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

View more
  15 in total

1.  Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.

Authors:  G T McInnes; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.

Authors:  M J Kerr; D W Harron; C Kinney; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

3.  Comparison of propranolol and propranolol LA in hypertension using 24-hr noninvasive blood pressure monitoring.

Authors:  M H Rustin; E N Coomes
Journal:  Postgrad Med J       Date:  1983-12       Impact factor: 2.401

4.  Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA).

Authors:  D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

5.  Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension.

Authors:  R G Wilcox; J R Hampton
Journal:  Br Heart J       Date:  1981-11

6.  Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers.

Authors:  D P Nicholls; D W Harron; J McAinsh; W M Castle; N P Barker; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 7.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

8.  Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris.

Authors:  M J Bowles; N S Khurmi; M J O'Hara; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

Authors:  F Theeuwes; D R Swanson; G Guittard; A Ayer; S Khanna
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

10.  Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.

Authors:  F B Müller; L F Allsopp; G L Cooper; P Bolli; P Frei; L Glaus; R Ritz; F R Bühler
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.